文献速递乳腺癌

转移性三阴性乳腺癌随机III期ASCENT试验最终结果及结局与人表皮生长因子受体2和滋养层细胞表面抗原2表达的关系

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
PubMed 文献 · J Clin Oncol · 2024-02-29

ASCENT研究比较戈沙妥珠单抗(SG)与医生选择化疗(TPC)用于转移性三阴性乳腺癌。最终分析显示SG组中位无进展生存期4.8个月对1.7个月(HR 0.41),中位总生存期11.8个月对6.9个月(HR 0.51),各Trop-2表达四分位组PFS均改善,安全性可控。

要点

  • SG组中位PFS 4.8个月,TPC组1.7个月,HR 0.41(95%CI 0.33-0.52)。
  • SG组中位OS 11.8个月,TPC组6.9个月,HR 0.51(95%CI 0.42-0.63)。
  • 各Trop-2表达四分位组SG均改善PFS,OS改善呈趋势。

核心结论

  • 最终分析数据证实SG较化疗具有临床获益,强化了SG作为转移性三阴性乳腺癌二线或后线有效治疗选择的地位。

研究设计与样本

  • 国际、多中心、III期ASCENT研究,患者按1:1随机接受SG或TPC直至不可接受毒性或疾病进展;最终分析中SG组n=267,TPC组n=262。

主要发现

  • SG组中位PFS为4.8个月,TPC组为1.7个月,HR 0.41(95%CI 0.33至0.52)。
  • SG组中位OS为11.8个月,TPC组为6.9个月,HR 0.51(95%CI 0.42至0.63)。
  • 在每个Trop-2表达四分位组(n=168)中SG均较TPC改善PFS;各四分位组OS改善呈趋势。
  • 总体安全性可控,因不良事件导致的治疗相关停药≤5%,无治疗相关死亡;安全性特征在所有亚组中一致。

临床怎么用

  • 原文结论指出SG是转移性三阴性乳腺癌二线或后线的有效治疗选择。

局限性

  • OS在各Trop-2表达四分位组中的改善仅为趋势观察,原文未报告该趋势的统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Sacituzumab govitecan (SG), a first-in-class anti-trophoblast cell surface antigen 2 (Trop-2) antibody-drug conjugate, demonstrated superior efficacy over single-agent chemotherapy (treatment of physician's choice [TPC]) in patients with metastatic triple-negative breast cancer (mTNBC) in the international, multicenter, phase III ASCENT study.Patients were randomly assigned 1:1 to receive SG or TPC until unacceptable toxicity/progression. Final efficacy secondary end point analyses and post hoc analyses of outcomes stratified by Trop-2 expression and human epidermal growth factor receptor 2 status are reported. Updated safety analyses are provided.In this final analysis, SG (n = 267) improved median progression-free survival (PFS; 4.8 v 1.7 months; hazard ratio (HR), 0.41 [95% CI, 0.33 to 0.52]) and median overall survival (OS; 11.8 v 6.9 months; HR, 0.51 [95% CI, 0.42 to 0.63]) over TPC (n = 262). SG improved PFS over TPC in each Trop-2 expression quartile (n = 168); a trend was observed for improved OS across quartiles. Overall, SG had a manageable safety profile, with ≤5% of treatment-related discontinuations because of adverse events and no treatment-related deaths. The safety profile was consistent across all subgroups.These data confirm the clinical benefit of SG over chemotherapy, reinforcing SG as an effective treatment option in patients with mTNBC in the second line or later.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bardia A, Rugo HS, Tolaney SM, et al. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. J Clin Oncol. 2024. PMID: 38422473. doi:10.1200/JCO.23.01409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。